



Official Website



Scan to Download Digital List

Email overseas@yifanyy.com

Web www.yifanyy.com



YIFAN Pharmaceutical

Committed to becoming a new contributor of expertise in the
global pharmaceutical and health industry

• *Biologics* • *Small Molecule* • *Synbio* • *Traditional Chinese Medicine*



亿帆医药创立于 2003 年，二十余年砥砺前行，现已跻身国际化专业医药企业行列。

公司聚焦大分子生物药、小分子化药、特色中药及合成生物等前沿领域，打造了符合国际标准的研发创新体系与生产质量平台。通过布局欧美及东南亚区域性业务中心，亿帆构建了研发、生产、商业化全链条协同机制，夯实了全球化运营根基。以此为依托，亿帆医药的商业版图已拓展至全球 50 余个国家和地区。从小分子高端化药研发硕果累累、特色中药成功出海，维生素 B5 系列产品的全球领先市场份额，到大分子生物创新药“亿立舒”在欧美的成功上市，再到覆盖广泛市场的商业服务体系，亿帆逐步发展为国内屈指可数的、同时实现国内市场精耕、亚太区域辐射及新兴市场覆盖的中国制药企业，建立起横跨本土与海外的立体化营销网络，充分彰显了其在国际化竞争中的独特优势。

面向未来，亿帆将继续坚持“双向全球化”发展路径：推动中国创新走向世界，同时将全球优质药品引入中国，双向赋能，为全球患者创造更高价值的健康解决方案。

YIFAN Pharmaceutical, founded in 2003, has evolved into a leading international enterprise dedicated to delivering superior global health solutions. With fully integrated R&D, manufacturing and commercialization spanning Europe, the US and Southeast Asia. YIFAN has reaped fruitful achievements in the R&D of high-end small-molecule drugs and seen its specialty Traditional Chinese Medicine (TCM) successfully expand globally. It also holds a leading global position in Vitamin B5. Our innovative biologic product Ryzneuta® has secured landmark approvals from both the FDA and EMA. As one of the few Chinese pharmaceutical companies with a strong domestic presence and a commercial network across over 50 countries, we champion a globalization strategy - driving pioneering Chinese innovations onto the world stage while introducing premium overseas therapies to China, creating value for patients worldwide.



01 | Biological Product List

Novel Biologics | Biosimilar | Tool Enzyme

Marketed Novel Biological Product

Indication	Product Name	Target	Dosage Form & Strength	Regulatory Approvals
Chemotherapy-induced neutropenia (CIN)	Efbemalenograstim alfa injection (Ryzneuta®)	G-CSF	Subcutaneous injection in PFS; 1ml:20mg	NMPA: May. 2023 FDA: Nov. 2023 EMA: Mar. 2024 ANVISA: Dec.2024

Novel Biological Products Under Development

Indication	Product Name	Target	Status	Remarks
Alcoholic hepatitis (AH) Acute-on-chronic liver failure (ACLF) Acute graft versus host disease (aGVHD)	Recombinant human interleukin22-Fc fusion protein Injection (F-652)	IL-22	Phase II a completed	* Good safety profiles obtained from 200+ subjects in US, China and Australia * F-652 monotherapy or in combination with steroids shows a trend for improved efficacy in phase 2a studies * FDA granted the Orphan Drug Designation
Growth hormone deficiency	Recombinant human growth hormone-Fc fusion protein Injection (F-899)	GH	Phase Ia completed	* Longer elimination half-life, supporting longer administration intervals
Tumors	Recombinant human interleukin15-Fc fusion protein Injection (N-3C01)	IL-15	Phase I on going	* Extended half-life enables less frequent dosing, enhancing patient adherence * Structure-guided fusion protein optimization maximizes both stability and therapeutic potency

Marketed Biosimilar Products					
Indication	Product Name	Reference Drug	Dosage Form & Strength	Remarks	
Diabetes	Recombinant Human Insulin Injection (GENSULIN® R/ SciLin® R) *Short acting	Humulin® R Eli Lilly	Cartridges 3 mL (100 IU/mL) Vials 10 mL (100 IU/mL)	· High purity · Long shelf life – 36 months · In-use stability confirmed in studies up to 30°C and 75% relative humidity · High efficacy, safety and tolerability · Manufactured in compliance with the EU GMP standards *Human-identical structure minimizes immunogenicity *20 years on the market with comprehensive data: glycemic control comparable to reference insulin without increased hypoglycemia risk	
	Isophane Protamine Recombinant Human Insulin Injection (GENSULIN® N/ SciLin® N) *Intermediate acting	Humulin® N Eli Lilly			
	Mixed Protamine Human Insulin Injection (3OR) (GENSULIN® M30/ SciLin® M30) * Bi-phasic	Humulin® 30/70 Eli Lilly			

Biosimilar Products Under Development						
TA	Product Name	Reference Drug	Status	CP/EP /USP	US DMF	Remarks
Growth hormone deficiency	Somatropin	Norditropin® / Novo Nordisk	Phase I on going; API/BDP marketable	Y	Y	*Prokaryotic Expression Platform for Peptide Hormones Independently developed with streamlined and stable processes. Significantly improves yield while reducing production costs *In-House Synthesis of Key Raw Materials Side-chain raw materials synthesized internally to ensure quality control Mitigates supply chain risks and further lowers costs *High-Yield Engineered Bacterial Strains Fusion protein expression exceeds 35% of total bacterial protein *Proprietary Tool Enzymes Self-developed enzymes simplify purification and increase recovery rates
Diabetes	Insulin glargine *Long-acting	Lantus® / Sanofi	IND approval API marketable	Y	Y	
	Insulin degludec *Ultralong-acting	Tresiba® / Novo Nordis	Pre-clinical API marketable	Y	Y	
	Insulin aspart *Short acting	NovoRapid® / Novo Nordisk	Pre-clinical API marketable	Y	Y	
Osteoporosis	Teriparatide	Forteo® / Eli Lilly	Phase I on going; API/BDP marketable	Y	Y	

Marketable Tool Enzymes (Recombinant)				
Product	Expression System	Cleavage/Digestion	Usage	Potency
Trypsin	E. coli	Precise Cleavage at Lysine and Arginine C-terminal Peptide Bonds: Highly specific proteolytic activity exclusively targeting peptide bonds C-terminal to lysine (K) and arginine (R) residues.	*Alternative therapy for indigestion *Food Industry: Protein hydrolysis modification *Biotech/Pharmaceutical Industries: Enzymatic digestion of proteins and peptide mapping	Specific Activity ≥ 5000 U/mg
Carboxypeptidase-B (CPB)		Exclusively hydrolyzes peptide bonds at the C-terminus of proteins, preferentially releasing basic amino acids (lysine K, arginine R); minimal activity towards histidine (H).	*Biotech/Pharmaceutical Industries: Enzymatic digestion of proteins	Specific Activity ≥ 100 U/mg
Lys-C		Highly Specific Lysyl Peptide Bond Cleavage: Exclusive enzymatic digestion of peptide bonds C-terminal to lysine residues (Lys at P1 position), even in the presence of denaturants like urea. Complete specificity for lysyl-endopeptidase activity with no observed off-target hydrolysis.	*Biotech/Pharmaceutical Industries:Enzymatic digestion of proteins and peptide mapping	Specific Activity ≥ 20 U/mg
Enterokinase (light chain) *liquid	Yeast	Specific hydrolysis at DDDDK↓X motifs (cleavage C-terminal to lysine in tetra-aspartate sequences), with no non-specific cleavage of other peptide bonds.	*Biotech/Pharmaceutical Industries: Enzymatic digestion of fusion proteins	Specific Activity 5.0 U/μL*
Kex-2 Protease		Specifically recognizes and cleaves peptide bonds C-terminal to dibasic amino acid motifs, including arginine-arginine (RR) and lysine-arginine (KR), with no off-target cleavage.	*Biotech/Pharmaceutical Industries: Enzymatic digestion of fusion proteins	Specific Activity ≥ 10 U/mg

02 | Small Molecule
Product List

Formulation | TCM | API | Excipient | Intermediate

Chemicals
化药成品

TA 治疗领域	Product 品种	Strength 规格	China 中国市场	Overseas 海外市场
Hematologic Malignancy 血液肿瘤	Clofarabine Injection 氯法拉滨注射液	20ml:20mg	Marketed 已上市	ready to file
	Plerixafor Injection 普乐沙福注射液	1.2ml:24mg	Marketed 已上市	ready to file
	Vincristine Sulfate Injection 硫酸长春新碱注射液	1ml:1mg	Marketed 已上市	under EU registration
	Vincristine Sulfate Injection 硫酸长春新碱注射液	10ml:10mg	Under registration 注册中	ready to file
	Vinorelbine Tartrate Injection 酒石酸长春瑞滨注射液	1ml:10mg	Under registration 注册中	ready to file
	Vindesine Sulfate for Injection 注射用硫酸长春地辛	1mg	Under development 在研	dossier under preparation
	Carfomil for Injection 注射用卡非佐米	60mg	Marketed 已上市	under EU registration
	Cytarabine for Injection 注射用阿糖胞苷	0.1g; 0.5g	Marketed 已上市	ready to file
	Epirubicin Hydrochloride for Injection 注射用盐酸表柔比星	10mg	Marketed 已上市	ready to file
	Ixazomib Citrate Capsules 枸橼酸伊沙佐米胶囊	2.3mg、3mg、4mg	Under registration 注册中	dossier under preparation
	Tretinoin Soft Capsules 维A酸软胶囊	10mg	Under development 在研	dossier under preparation

Chemicals 化药成品				
TA 治疗领域	Product 品种	Strength 规格	China 中国市场	Overseas 海外市场
Solid Tumor 实体瘤	Vinorelbine Tartrate Soft Capsules 酒石酸长春瑞滨软胶囊	20mg	Under development 在研	dossier under preparation
	Niraparib Tosylate Capsules 甲苯磺酸尼拉帕利胶囊	100mg	Under development 在研	dossier under preparation
	Selumetinib Hydrogen Sulfate Capsules 硫酸氢司美替尼胶囊	10mg	Under development 在研	dossier under preparation
	Abemaciclib Tablets 阿贝西利片	150mg、100mg、 50mg	Under development 在研	under EU registration
Gynecology and obstetrics 妇产科	Oxytocin Injection 缩宫素注射液	10IU	Marketed 已上市	CIS approved
	Oxytocin Nasal Spray 缩宫素鼻喷雾剂	5ml:200IU	Marketed 已上市	under EU registration
Anti-Infective 抗感染	Isavuconazonium Sulfate for Injection 注射用硫酸艾沙康唑	200mg	Marketed 已上市	under EU registration
	Amikacin Sulfate Injection 硫酸阿米卡星注射液	2ml:500mg	Marketed 已上市	EU marketed
Rare disease 罕见病	Diazoxide Oral Suspension 二氮嗪口服混悬液	30ml:1.5g	Marketed 已上市	ready to file
	Selumetinib Hydrogen Sulfate Capsules 硫酸氢司美替尼胶囊	10mg	Under development 在研	dossier under preparation

Chemicals 化药成品				
TA 治疗领域	Product 品种	Strength 规格	China 中国市场	Overseas 海外市场
CKD-associated pruritus 慢性肾脏病相关瘙痒症	Difelikefalin Acetate Injection 醋酸地非法林注射液	50µg/ml(1.3ml)	Under registration 注册中	ready to file
Heparin Antagonist 抗肝素药	Protamine Sulfate Injection 硫酸鱼精蛋白注射液	5ml:50mg	Under development 在研	ready to file
Vitamin 维生素类	Vitamin K1 Injection 维生素K1注射液	0.2ml: 2mg 1ml: 10mg	Marketed 已上市	ready to file
Central analgesics 中枢镇痛药	Eptazocine Hydrobromide Injection 氢溴酸依他佐辛注射液	1ml:15mg	Marketed 已上市	ready to file
First-aid 急救	Norepinephrine Bitartrate Injection 重酒石酸去甲肾上腺素注射液	4ml	Marketed 已上市	PICS approved
	Phenylephrine Hydrochloride Injection 盐酸去氧肾上腺素注射液	1ml:10mg	Marketed 已上市	ready to file
	Dopamine Hydrochloride Injection 盐酸多巴胺注射液	5ml: 100mg	Marketed 已上市	ready to file
Pain relief 镇痛	Phloroglucinol Injection 间苯三酚注射液	4ml:40mg/40µg	Marketed 已上市	ready to file
Muscle relaxant 肌肉松弛药物	Methocarbamol Injection 美索巴莫注射液	10ml:1g	Marketed 已上市	ready to file
	Neostigmine Methylsulfate Injection 甲硫酸新斯的明注射液	1ml:0.5mg 2ml:1mg 4ml:2mg	Marketed 已上市	ready to file

API LIST 原料药产品			
MOLECULES 产品名称	CAS No.	TA 治疗领域	Registration 备案情况
Melatonine 褪黑素	73-31-4	API for drug for regulating sleep and maintain a sleep cycle. 调节睡眠（口服制剂）	US DMF#42897
Diazoxide 二氮嗪	364-98-7	API for medicine for treating congenital hyperinsulinemic hypoglycemia (CHI) and emergency treatment of hypertensive crisis. 先天性高胰岛素性低血糖血症；高血压危象的急救（口服或注射剂）	US DMF#42890
Diazoxide Choline 二氮嗪胆碱	1098065-76-9	API for medicine for the treatment of hyperphagia in adult and pediatric patients with Prader-Willi syndrome (PWS) aged 4 years and older. 用于4岁及以上患有Prader-Willi综合征（PWS）的成人和儿科患者的食欲亢进的治疗(缓释片)	Marketable 可售
Azacytidine 阿扎胞苷	320-67-2	API for drug for leukemia, such as acute myeloid leukemia, acute lympho-blastic leukemia, chronic myeloid leukemia, etc. 白血病，如急性髓系白血病、急性淋巴细胞白血病、慢性粒细胞白血病急变期等（注射剂）	US DMF#43196
Cytarabine 阿糖胞苷	147-94-4	API for drug for leukemia, such as acute myeloid leukemia, chronic myeloid leukemia. 急性髓系白血病、慢性髓系白血病（急变期）的诱导缓解和维持治疗（注射剂）	US DMF#43089
Emedastine Difumarate 富马酸依美斯汀	87233-62-3	API for medicine as antihistaminic, H1-receptor; asthma prophylactic; anti-allergic. 过敏性鼻炎和荨麻疹（口服缓释胶囊）	Marketable 可售
Plerixafor 普乐沙福	110078-46-1	API for drug for non-Hodgkinlymphoma. 非霍奇金淋巴瘤和多发性骨髓瘤（注射剂）	Marketable 可售
Clofarabine 氯法拉滨	123318-82-1	API for drug as broad-spectrum anti-tumor drugs. 广谱抗肿瘤（注射剂）	Marketable 可售
Oxytocin 缩宫素	50-56-6	API for drug for uterine contraction. 子宫出血；了解胎盘储备功能（激惹试验）；催乳和促进产妇生产（注射剂）	Marketable 可售
Eptazocine hydrobromide 氢溴酸赛他佐辛	72150-17-5	API for drug for relieving cancer pain and postoperative pain. 癌痛及手术后疼痛（注射剂）	Marketable 可售

API LIST 原料药产品			
MOLECULES 产品名称	CAS No.	TA 治疗领域	Registration 备案情况
Dapoxetine Hydrochloride 盐酸达泊西汀	129938-20-1	API for drug for premature ejaculation. 男性早泄（口服制剂）	Marketable 可售
Vindesine Sulfate 硫酸长春地辛	59917-39-4	Mainly used for the treatment of non-small cell lung tumor, small cell lung tumor, malignant lymphoma, esophageal tumor, breast tumor and malignant melanoma and other malignant tumors: It can also treat children with other drug-resistant acute lymphoblastic leukemia, chronic myeloid leukemia in the acute stage, and malignant lymphoma that does not respond to treatment. 主要用于治疗非小细胞肺癌、小细胞肺癌、恶性淋巴瘤、食管瘤、乳腺癌及恶性黑色素瘤等恶性肿瘤;亦可以治疗其它药物耐药的急性淋巴细胞白血病的儿童患者、慢性粒细胞白血病急变期、对治疗无反应的恶性淋巴瘤。	Marketable 可售
Difelikefalin 醋酸地非法林	1024828-77-0	Itching caused by hemodialysis, renal disease-related itching, chronic kidney disease with moderate to severe itching. 血液透析引起的瘙痒、肾脏疾病相关性瘙痒、慢性肾病伴中重度瘙痒（注射剂）	US DMF#43195
Carfilzomib 卡非佐米	868540-16-3	API for drug for multiple myeloma 多发性骨髓瘤（注射剂）	Marketable 可售
Ixazomib citrate 枸橼酸伊沙佐米	1201903-02-7	API for drug for multiple myeloma. 多发性骨髓瘤（口服制剂）	Marketable 可售
Selumetinib bisulfate 硫酸氢司美替尼	606144-05-2	Treatment of pediatric patients with type 1 neurofibromatosis (NF1) who are 3 years old and above with symptoms and inoperable plexus neurofi-bromatosis (PN) 用于3岁及3岁以上伴有症状、无法手术的丛状神经纤维瘤(PN)的1型神经纤维瘤病(NF1)儿科患者的治疗。（口服制剂）	Marketable 可售
Trofinetide 曲非奈肽	853400-76-7	API for drug for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older. 用于治疗2岁及以上成人和儿童患者的Rett综合征（口服溶液剂）	being developed 在研
Centanafadine Hydrochloride 盐酸赛他发定	923981-14-0	API for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children, adolescents and adults. 用于治疗儿童、青少年和成人的注意力缺陷多动障碍（ADHD）	being developed 在研

API LIST 原料药产品			
MOLECULES 产品名称	CAS No.	TA 治疗领域	Registration 备案情况
Ribociclib succinate 琥珀酸瑞波西利	2762182-61-4	Applicable to hormone receptor (HR) -positive, human epidermal growth factor receptor 2 (HER2) -negative locally advanced or metastatic breast cancer, and is used in combination with aromatase inhibitors as the initial endocrine therapy for female patients. 适用于激素受体（HR）阳性、人表皮生长因子受体2（HER2）阴性局部晚期或转移性乳腺癌，与芳香化酶抑制剂联合用药作为女性患者的初始内分泌治疗。	Marketable 可售
Difamilast 地法米司特	1574285-43-0	Treatment of mild to moderate atopic dermatitis in patients aged 3 months and older 3个月及以上轻至中度特应性皮炎（外用制剂）	Marketable 可售
Niraparib Tosylate 甲苯磺酸尼拉帕利	1476776-84-7	1) Maintenance treatment of adult patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. 2) Maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 1) 铂敏感的复发性上皮性卵巢癌、输卵管癌或原发性腹膜癌成人患者在含铂化疗达到完全缓解或部分缓解后的维持治疗； 2) 晚期上皮性卵巢癌、输卵管癌或原发性腹膜癌成人患者对一线含铂化疗达到完全缓解或部分缓解后的维持治疗（口服制剂）	Marketable 可售
Miglustat 麦格司他	72599-27-0	1) API for drug for the oral treatment of adult patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option. 2) API for drug for the treatment of progressive neurological manifestations in adult and pediatric patients with Niemann-Pick disease type C. 1)用于无法使用酶替代疗法的轻度至中度1型戈谢病成年患者的口服治疗； 2)用于成人及儿童C型尼曼匹克病患者的进行性神经症状的治疗(口服胶囊剂)	being developed 在研
Glycerol phenylbutyrate 苯丁酸甘油酯	611168-24-2	API for drug for use as a nitrogen-binding agent for chronic management of patients 2 months of age and older with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation aloneFDA Access Data. 适用于不能限制蛋白质的摄入和/或单纯补充氨基酸控制的尿素循环障（UCDs）患者的长期治疗（口服液）	Marketable 可售

Excipients List 辅料清单			
MOLECULES 产品名称	CAS No.	TA 治疗领域	Registration 备案情况
Glycocholic acid 甘氨酸胆酸	475-31-0	Carrier of insoluble drugs 难溶性药物的载体	Marketable 可售
Glyceryl Monostearate 单硬脂酸甘油酯	31566-31-1	Inactive ingredient for drugs as pearlescent dispersant, solubilizer, lubricant. 表面活性剂、乳化剂、分散剂、消泡剂	Marketable 可售
Palmitic acid 棕榈酸	1957-10-3	Inactive ingredients for drugs as ointment matrix, lubricant. 润滑剂和软膏基质，广泛用于口服和外用制剂	Marketable 可售
Lauric acid 月桂酸	143-07-7	Inactive ingredients for drugs as absorption promoter, stabilizer. 局部渗透和透皮吸收、直肠吸收、口腔输送和肠道吸收的促进剂;稳定水包油乳液	Marketable 可售
Myristic acid 肉豆蔻酸	544-63-8	Inactive ingredient for drugs as defoamer and ointment matrix. 消泡剂和软膏基质，用于口服和外用药物制剂	Marketable 可售

Intermediate List 中间体清单	
MOLECULES 产品名称	CAS No.
Centanafadine 赛他发定（游离碱）	924012-43-1
Emedastine 依美斯汀（游离碱）	87233-61-2
Ethyl 2-Piperidone-3-carboxylate 3-甲酸乙酯-2-哌啶酮	3731-16-6
2-chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid 2-氯-7-环戊基-7H-吡咯并[2,3-d]嘧啶-6-甲酸	3731-16-6
3-(4-bromophenyl)-Piperidine 3-(4-溴苯基)哌啶	769944-72-1
(3S)-3-(4-Bromophenyl) piperidine (3S)-3-(4-溴苯基)哌啶	1335523-82-4

Traditional Chinese Medicine (TCM) Products 特色中药产品			
Product 品种	Strength 规格	Indication 适应症	Remark 备注
Oral Arsenic Realgar-Indigo Naturalis Formula 复方黄黛片	0.27g/tablet 100 tablets/bottle 每片 0.27g, 100 片/瓶	Clear heat and detoxifying, supplementing Qi and producing blood. For initial treatment of acute myeloid leukaemia. 清热解毒，益气生血。用于初治的急性早幼粒细胞白血病。	1.WHO Essential Drug List, 2019 2.European Leukemia Net (ELN), 2019 3.Chinese Essential Drug List, 2018 1.WHO基药目录,2019年版 2.欧洲白血病工作网专家共识，2019 年版 3.中国基药目录,2018年版
Compound Yinhua iedu Granules 复方银花解毒颗粒	15g/sachet, 6 sachets/box 每袋 15g, 6 袋/盒	Disperse wind, clear heat and detoxify by dispelling pathogenic factors through the exterior part of the body. Used for common cold and influenza associated with wind-heat syndrome. Relief of symptoms including fever, slight aversion to wind, headache, stuffy running nose, cough, sore throat, whole body aching pain, white or yellow tongue coating with faintly visible tongue surface, superficial and rapid pulse. 疏风解表，清热解毒。用于普通感冒、流行性感冒属风热证，症见：发热，微恶风，头痛，鼻塞流涕，咳嗽，咽痛，全身酸痛，苔薄白或微黄，脉浮数。	Approved by HSA in 2025 2025年新加坡上市获批
Maqin Xiaoke Granules 麻芩消咳颗粒	8g/sachet 6 sachets/box 每袋8g, 6袋/盒	Clear lung fire and resolve phlegm, suppress cough and to calm panting. Used for acute bronchitis and acute episode of chronic bronchitis with syndrome of phlegm-heat obstructing the lung. Relief of symptoms including cough, dyspnea, expectoration of yellow or thick sputum, fever, dry mouth, yellow greasy tongue coating, reddened tongue, etc. 清肺化痰，止咳平喘。用于急性支气管炎、慢性支气管炎急性发作属痰热郁肺证，症见：咳嗽、喘息、痰黄或稠厚、发热、口干、苔黄腻、舌红等症。	Approved by HSA in 2025 2025年新加坡上市获批

Traditional Chinese Medicine (TCM) Products 特色中药产品			
Product 品种	Strength 规格	Indication 适应症	Remark 备注
Piminxiao Capsules 皮敏消胶囊	0.4g/capsule, 10 capsules/blister ×2 blisters /box; 12 capsules/blister ×2 blisters/box 每粒装0.4g, 10粒/板 ×2板/盒; 12粒/板×2板/盒	Dispel wind and remove dampness, clear heat and detoxify, cool blood and relieve itching, for acute and chronic urticaria, acute eczema is wind-heat syndrome or wind-heat with dampness syndrome. 祛风除湿，清热解毒，凉血止痒，用于急慢性荨麻疹、急性湿疹属风热证或风热挟湿证者。	Approved by HSA in 2025 2025年新加坡上市获批
Ginkgo Leaf Pills 银杏叶丸	0.2g/bottle (contains total flavone glycosides 9.2mg, terpene lactones 4.8mg), 0.2g/bottle× 6 bottles/blister ×2 blisters/box 每瓶装0.2g（含总黄酮 醇苷19.2mg, 萜类内酯 4.8mg）， 0.2g/瓶×6瓶/板×2板/盒	To promote blood circulation, remove stasis, and free the collateral vessels. It is used for chest impediment, heart pain, wind stroke, hemiplegia, and sluggish speech caused by blood stasis obstructing the collaterals; stable angina pectoris of coronary heart disease and cerebral infarction with the above syndromes. 活血化瘀通络。用于瘀血阻络引起的胸痹、心痛、中风、半身不遂、舌强语蹇，冠心病稳定型心绞痛、脑梗塞见上述证候者。	Approved by HSA in 2025 2025年新加坡上市获批
Chushi Zhiyang Ointment 除湿止痒软膏	10g/tube , 20g/tube 每支 10g, 每支 20g	Clearing heat and removing dampness, dispelling wind and relieving itch. It is used for the auxiliary treatment of acute and subacute eczema which is damp-heat or damp-resistance type. 清热除湿，祛风止痒。用于急性、亚急性湿疹证属湿热或湿阻型的辅助治疗。	Approved by HSA in 2025 2025年新加坡上市获批

Fisiopharma Approved
Fisiopharma已批准产品

MOLECULES 产品名称	FORMUALTION 剂型	STRENGTHS 规格	EU 欧洲	M.A. # 注册证号	
Bupivacaine hydrochloride 盐酸布比卡因	Injection 注射剂	2.5mg/ml * 5ml 2.5mg/ml * 10ml - ampoules 5.0mg/ml * 5ml 2.5mg/ml * 10ml - ampoules	Approved 已批准	035246014 035246038	035246026 035246040
Sugammadex sodium 舒更葡糖钠	Injection 注射剂	100mg/ml - 2ml 1 vial 100mg/ml - 2ml 10 vials 100mg/ml - 5ml 1 vial 100mg/ml - 5ml 10 vials	Approved 已批准	050534015 050534027	050534039 050534041
Midazolam hydrochloride 盐酸咪达唑仑	Injection 注射剂	5mg/1ml – 1 ampoule 5mg/1ml – 5 ampoules 5mg/1ml – 10 ampoules 15mg/3ml – 1 ampoule 15mg/3ml – 5ampoules 15mg/3ml – 10 ampoules	Approved 已批准	037263011 037263035 037263050	037263023 037263047 037263062
Triamcinolone acetonide 醋酸曲安奈德	Injection 注射剂	40mg/1ml – 3 vials 80mg/2ml – 3 vials 80mg/2ml – 5 ampoules	Approved 已批准	034262016 034262030	034262028
Tobramycin 妥布霉素	Injection 注射剂	100mg/2ml 150mg/2ml	Approved 已批准	035132036	035132048
Water for injection 注射用水	Injection 注射剂	10ml – 10 ampoules	Approved 已批准	031405246	
Chloramphenicol sodium succinate 氯霉素琥珀酸钠	Injection 注射剂	1g/10ml - 1 vial powder + 1 ampoule solvent	Approved 已批准	031414016	
Chloramphenicol sodium succinate 氯霉素琥珀酸钠	Injection 注射剂	1g – 10 vials powder	Approved 已批准	031414028	

Fisiopharma Approved
Fisiopharma已批准产品

MOLECULES 产品名称	FORMUALTION 剂型	STRENGTHS 规格	EU 欧洲	M.A. # 注册证号	
Erythromycin Lactobionate 乳糖酸红霉素	Injection 注射剂	1g/20ml - 1 vial powder + 1 ampoule 20 ml solvent 500mg/10ml – 1 vial powder + 1 ampoule solvent	Approved 已批准	031421023C	031421011
Furosemide 呋塞米	Injection 注射剂	20mg/2ml 5 ampoules 10 ampoules 50 ampoules 100 ampoules	Approved 已批准	031422013 031422037	031422025 031422049
Gentamicin sulphate 硫酸庆大霉素	Injection 注射剂	80mg/2ml 1 ampoule 10 ampoules 50 ampoules 100 ampoules	Approved 已批准	031423027C 031423066	031423066 031423080
Gentamicin sulphate 硫酸庆大霉素	Injection 注射剂	40mg/2ml 1 ampoule 10 ampoules 50 ampoules 100 ampoules	Approved 已批准	031423015 031423041	031423039 031423041
Lidocaine hydrochloride 盐酸利多卡因	Injection 注射剂	200mg/10ml – 5 ampoules 10 ampoules 50 ampoules 100 ampoules	Approved 已批准	031425022 031425073	031425061 031425085
Lidocaine hydrochloride 盐酸利多卡因	Injection 注射剂	50mg/10ml – 5 ampoules 10 ampoules 50 ampoules 100 ampoules	Approved 已批准	031425010 031425046	031425010 031425059
Dobutamine hydrochloride 盐酸多巴酚丁胺	Injection 注射剂	250mg/20ml – 1 vial	Approved 已批准	033609013	
Vancomycin hydrochloride 盐酸万古霉素	Injection 注射剂	500mg – 10 vials 1g – 1 vial	Approved 已批准	034634030	034634028

Pharmatex Italia Approved
Pharmatex Italia已批准产品

MOLECULES 产品名称	FORMUALTION 剂型	STRENGTHS 规格	EU 欧洲	M.A. # 注册证号	
Amikacin sulphate 硫酸阿米卡星	Injection 注射剂	500mg/2ml – 10 ampoules	Approved 已批准	024459137	
Cefotaxime 头孢噻肟	Injection 注射剂	1 vial powder of 500mg+solv 2ml 1 vial powder of 1g+solv 4ml 1 vial powder of 1g+solv 4ml with lidocaine 1 vial powder of 2g+solv 10 ml	Approved 已批准	035068016 035068030	035068028 035068042
Heparin sodium 肝素钠	Injection 注射剂	5000 UI/1ml10 ampoules 25000 UI/5ml 10 ampoules 25000 UI /5ml 1 vials 10 vials	Approved 已批准	034692032 034692018	034692020 034692044
Potassium aspartate 天冬氨酸钾	Injection 注射剂	10 mEq/10ml 30 mEq/10ml	Approved 已批准	036918011	036918023
Pamidronic acid 帕米膦酸	Injection 注射剂	30mg/10ml 60mg/10ml 90mg/10ml	Approved 已批准	036645024 036645048	036645036
Piperacillin 哌拉西林	Injection 注射剂	1g vial + 2ml ampoule 2g vial + 4ml ampoule	Approved 已批准	033958012 033958036	033958024
Piperacillin/tazobactam 哌拉西林/他唑巴坦	Injection 注射剂	2g+250mg/4ml - vial + ampoule 4g+500mg -1 vial 4g+500mg -10 vials	Approved 已批准	038558019 038558033	038558021
Vancomycin hydrochloride 盐酸万古霉素	Injection 注射剂	500mg - 1 vial 500mg - 10 vials 1g - 1 vial	Approved 已批准	034632012 034632024	034632036
Triamcinolone acetonide 氯霉素琥珀酸钠	Injection 注射剂	40mg/1ml – 3 vials 80mg/2ml – 3 vials	Approved 已批准	033919010	033919022

03

Synthetic Biology

Product List

CAS No.	Product Name	Application
137-08-6	VitaminB5/CalciumPantothenate USP/BP/EP/IP	Widely used in food and animal feed, multi-vitamin capsule, tablets, energy drinking etc.
58-56-0	VitaminB6 / Pyridoxine Hydrochloride	Widely used in food and feed industry. Used as a nutritional supplement and enhancer in the food industry. In livestock and poultry breeding, this product is used as a vitamin feed additive.
41263-94-9 157574-76-0	Human Milk Oliosaccharides: 2'-FL 6'-SL	Has various physiological functions such as improving gut microbiota, regulating immu- nity, and promoting neural development. Children's formulated milk, infant formula, complementary foods for infants and young children, infant formula foods for special medical purposes, functional foods, and the fields of pharmaceuticals and health products.
81-13-0	D-Panthenol USP/BP/EP/IP D-Panthenol 75%W D-Panthenol 50%P D-Panthenol 50%W	Pro-Vitamin B5 series D-Panthenol is the provitamin of D-Pantothenic acid (Vitamin B5), which plays a key role in human intermediary metabolism. As an active As an active ingredient in cosmetics, such as skin care and hair care products, D-panthenol is a part of Coenzyme A - Role in the skin: 1. Deep-penetrating moisturizer 2. Stimulates epithelization 3. Has wound-healing effect 4. Has an anti-inflammatory effect - Role in the hair: 1. Long-lasting moisturizer 2. Prevents hair damage 3. Thickens hair 4. Improves luster and sheen - Role in nail care: 1. Improves hydration 2. Imparts flexibility
16485-10-2	DL-Panthenol USP DL-Panthenol 50%W	
667-83-4	D-Panthenyl Ethyl Ether	
667-84-5	DL-Panthenyl Ethyl Ether	
599-04-2	D-(-)-Pantolactone	Ingredient for cosmetics, intermediate for Calcium Pantothenate, D/DLPanthenol, Pantethine, etc
109-78-4	3-Hydroxypropionitrile	Preparation of luminescent substrates of luminescent reagents, electrolyte additives for new energy batteries
156-87-6	3-Aminopropanol	Mainly for synthesis of D/DL-Panthenol, and to synthesize cyclophosphamide, cardiac and other drugs